• Fulvestrant (ICI 182,780): Redefining Estrogen Receptor A...

  2025-10-22

  Explore how Fulvestrant (ICI 182,780), a potent estrogen receptor antagonist, is transforming ER-positive breast cancer treatment and resistance research. This article delves deeper into immunological mechanisms, cell fate modulation, and translational strategies, setting itself apart from conventional narratives.

• Sunitinib: Multi-Targeted RTK Inhibitor for Cancer Therap...

  2025-10-21

  Sunitinib’s multi-targeted receptor tyrosine kinase inhibition is revolutionizing anti-angiogenic cancer therapy workflows, especially in models of renal cell carcinoma and nasopharyngeal carcinoma. With potent, nanomolar-range activity and proven synergy in ATRX-deficient glioma research, Sunitinib enables precise dissection of RTK signaling and apoptosis induction in preclinical settings.

227 records 16/16 page Previous First page 上5页 16